Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 2 1

Status

Unknown 1Completed 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 48Lymphoid 16Plasma cell 9CNS 8Tumor-Agnostic 7Gastrointestinal 7Genitourinary 5Dermatologic 4Other hematologic neoplasm 3Breast 3Other solid neoplasm 2Gynecologic 2Sarcoma 1Head & Neck 1Endocrine 1

Conditions

Solid Tumors 1Relapsed Pediatric Solid Tumor 1

Interventions

Cisplatin 145pembrolizumab 129Carboplatin 125Injections 108Pemetrexed 97Paclitaxel 97Gemcitabine 85Irinotecan 75Nivolumab 71Cyclophosphamide 71Docetaxel 68Bevacizumab 57Oxaliplatin 49Fluorouracil 48atezolizumab 46Capecitabine 46Etoposide 42Leucovorin 41tislelizumab 40toripalimab 36fludarabine 32Ipilimumab 30Drug Therapy 30Topotecan 29durvalumab 28Vincristine 27Early Intervention, Educational 27Radiotherapy 26Interviews as Topic 26Specimen Handling 25

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Crizotinib × Other solid neoplasm × Clear all
NCT00828919 2024-12-03

Continuing Access to Axitinib (A406- AG- 013736 ) For Patients Previously Receiving AG 013736 In Clinical Trials

Pfizer

Phase NA Completed
52 enrolled 12 charts
Other solid neoplasm

Solid Tumors

NCT02638428 2020-03-19

Genomics-Based Target Therapy for Children With Relapsed or Refractory Malignancy

Samsung Medical Center

Phase 2 Unknown
90 enrolled
Other solid neoplasm

Relapsed Pediatric Solid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡